Brooke D. Jorgensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brooke D. Jorgensen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aline Talhouk
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
36 shared publications - Bryan M. McCauley
Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224
36 shared publications - Chen Wang
Mayo Clinic
36 shared publications - Dale W. Garsed
Peter MacCallum Cancer Centre, Melbourne, Australia
36 shared publications - David D. L. Bowtell
Peter MacCallum Cancer Centre, Melbourne, Australia
36 shared publications - Dinuka Ariyaratne
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
36 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 4: Correlations between Methylation at CpG Sites and TAP1 mRNA Expression
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 4: Correlations between Methylation at CpG Sites and TAP1 mRNA Expression
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 1: Methylation Signature Approximation
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 1: Methylation Signature Approximation
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 6: Multivariate Modeling of Time to Recurrence/Death Among Studies with Gene Expression Data
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 6: Multivariate Modeling of Time to Recurrence/Death Among Studies with Gene Expression Data
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 1: Characteristics of Study Participants with High Grade Serous Tubo-Ovarian Carcinoma by Contributing Study
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 1: Characteristics of Study Participants with High Grade Serous Tubo-Ovarian Carcinoma by Contributing Study
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 5: Modeling of Time to Recurrence/Death Among Studies with Gene Expression Data, excluding data from Previously Published Participants
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 5: Modeling of Time to Recurrence/Death Among Studies with Gene Expression Data, excluding data from Previously Published Participants
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 2: CpGs That Defined Previously Reported Methylation Subtypes Using a Semi-Supervised Clustering Approach
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 2: CpGs That Defined Previously Reported Methylation Subtypes Using a Semi-Supervised Clustering Approach
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 4: Multivariate Modeling of Methylation Signature Among Studies with Multiple Datatypes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Table 4: Multivariate Modeling of Methylation Signature Among Studies with Multiple Datatypes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 3: Immune Analysis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 3: Immune Analysis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Methods 1: The original 60 CpG loci defining methylation-based subtypes, and the approximation method for methylation signature
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Methods 1: The original 60 CpG loci defining methylation-based subtypes, and the approximation method for methylation signature
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 2: No Association between Methylation Signature and Baseline Clinical Factors
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
Supplementary Figure 2: No Association between Methylation Signature and Baseline Clinical Factors